Navigation Links
ReBuilder Medical Technologies, Inc.'s Recent Stock Price Volatility Explained
Date:11/23/2007

Unique Buying Opportunity Presented

CHARLES TOWN, W.Va., Nov. 23 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM), a provider of treatment for diabetic peripheral neuropathy and Molluscum Contagiosum, today announced it has successfully concluded analysis of the recent volatility of their stock price and presented it to the Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )

It appears that several institutional and corporate investors possibly got nervous over the sub-prime housing crisis and liquidated large portions of their portfolios. "Unfortunately, our equity was included in their programmed liquidation process. As a result, many individual investors followed suit, increasing the supply of stock available to purchase and driving down the price per share," according to David Phillips, Ph.D. CEO.

Meanwhile the company continued its steady growth as evidenced by the quarterly reports published on pinksheets.com. There was no bad news whatsoever relative to the actual operations of the company. "We are in better financial shape, in better marketing shape, in better R&D shape, and in better PR shape than ever before in our company's history," says Dr. Phillips.

"We have successfully renegotiated certain aspects of our original merger terms to reduce the possibility of any remaining large corporate holders of our equities from taking profits and dumping large blocks of our stock on the market. In addition, many of these original holders of large blocks of our equities have now liquidated the majority of their shares to individual investors. We expect that these new individuals may have the best long-term interests of our company in mind. This could have the desired effect of stabilizing the stock price and thus reflect the real value of our equities," states Dr. Phillips. He concluded his statement by saying, "Because I, personally, am an insider, I cannot buy my own company's stock. However, if I could, I would sell my dog if I had to, to buy some."

Beginning on Monday, November 26, 2007, RBRM will be releasing a series of twelve news releases that will describe several new initiatives that are very exciting and will help investors have a better understanding of the company's current success and plans to expand that success in the near future.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.


'/>"/>
SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):